We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Electromagnetic Tracking of Devices During Biopsy Procedures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01403727
Recruitment Status : Completed
First Posted : July 27, 2011
Last Update Posted : May 29, 2013
Information provided by (Responsible Party):
Philips Healthcare

Brief Summary:

The purpose of the trial is to evaluate the differences between PercuNav assisted and unassisted biopsy in the areas of CT radiation dose, procedure time and biopsy accuracy.

This prospective, randomized, controlled trial will compare the use of electromagnetic tracking and image guidance (CT) during biopsy procedures verses the typical CT image guided procedure alone.

Condition or disease
Liver Tumors

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 50 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Electromagnetic Tracking of Devices During Biopsy Procedures
Study Start Date : November 2011
Primary Completion Date : April 2013
Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy Liver Cancer
U.S. FDA Resources

Unassisted Biopsy - CONTROL GROUP
Routine biopsy needle placement and Physician blinded to needle location
Assisted Biopsy - STUDY GROUP
The physician will be shown the PercuNav screen and will correct the desired approach path.

Primary Outcome Measures :
  1. Radiation Dose [ Time Frame: 24 hrs ]
    The primary objective of this study is to assess and quantify any differences between assisted and unassisted CT guided biopsy procedures of the liver with respect to radiation dose.

Secondary Outcome Measures :
  1. Total procedure time [ Time Frame: 24 hrs ]
    Total procedure time is determined by the timespan of the moment the patient is accepted into the room (start) and the time when the procedure is complete (finish - when physician exits room).

  2. Accuracy of needle targeting [ Time Frame: 24 hrs ]
    Distance from defined target on PercuNav and angle of entry

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing a liver biopsy procedure

Inclusion Criteria:

  1. Has had a pre-operative CT scan performed and will be undergoing a biopsy procedure of the liver;
  2. Is over the age of 18;
  3. Has the ability to understand and the willingness to sign a written informed consent form, and complies with the protocol;
  4. Has the ability to follow procedural instructions, including, but not limited to, holding their breath and remaining reasonably motionless during the procedure.

Exclusion Criteria:

  1. Was precluded from a biopsy procedure based on standard exclusions;
  2. Has an adhesive allergy (due to the application of active fiducials with adhesive backing);
  3. Has a pacemaker or automatic implantable cardiac defibrillator;
  4. Has a gross body weight above 180lbs for women and 260lbs for men;
  5. Is pregnant

A patient may be excluded after enrollment if any of the following criteria are met:

1. The patient's health and/or safety become jeopardized for any reason making it unsafe to continue; 2. Technical errors and/or difficulties; 3. Any reasonable rationale put forth by the physician or investigator 4. Lost to follow up - In-evaluable data

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01403727

United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
Sponsors and Collaborators
Philips Healthcare
Principal Investigator: Edward Kim, MD Icahn School of Medicine at Mount Sinai

Responsible Party: Philips Healthcare
ClinicalTrials.gov Identifier: NCT01403727     History of Changes
Other Study ID Numbers: 2010_MtSinai_BiopTrial_V2
First Posted: July 27, 2011    Key Record Dates
Last Update Posted: May 29, 2013
Last Verified: May 2013

Keywords provided by Philips Healthcare:
Biopsy of liver tumors

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases